Alnylam is leading the translation of RNA interference (RNAi) into an innovative new class of medicines for patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically-validated approach for the treatment of a wide range of severe and debilitating diseases.

Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi discovery platform and deep pipeline of investigational medicines including two approved medicines in Canada, five programs in late-stage clinical development and multiple programs in early-stage clinical development.